FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washingto	n, D.C.	20549	
-----------	---------	-------	--

STATEMENT OF CHANGES IN BENE	FICIAL C	WNERSHIP

**OMB APPROVAL** 3235-0287 Estimated average burden hours per response 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  MEHTA VIREN					2. Issuer Name and Ticker or Trading Symbol Onconova Therapeutics, Inc. [ ONTX ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X Director 10% Owner					
(Last) (First) (Middle) C/O ONCONOVA THERAPEUTICS, INC. 375 PHEASANT RUN				1	1/25/2	2019			`	h/Day/Year)		Officer (give title Other (specify below) below)  6. Individual or Joint/Group Filing (Check Applicable						
(Street) NEWTO (City)		A state)	18940 (Zip)		_   <sup>4.</sup>	IT AME	enament, L	Jate	ot Origii	паі ніі	ed (Month/Da	ly/Year)	Lin	e) X Form fil	ed by	One Repo	(Check App rting Persor One Repor	1
(- 3)				Non-De	rivati	ve Se	curities	s Ad	cquire	ed, D	isposed o	of, or Be	eneficial	ly Owned				
1. Title of Security (Instr. 3)		2. Transa Date (Month/D	action	Execution Date,		te,	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and		(A) or	5. Amount of Securities Beneficially Owned Following		6. Owners Form: Dir (D) or Ind (I) (Instr. 4	ect Indir irect Bend 4) Own	7. Nature of Indirect Beneficial Ownership		
								Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)			(Inst	(Instr. 4)	
Common	Common Stock 11/25/2			/2019				P		250,000	A	\$0.2(1)	250,857	(2)	D			
Common Stock											54		I By I					
Common Stock												56		I		Viram Indation <sup>(4)</sup>		
			Table I								posed of, , converti			Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year) (Month/I						6. Date Exerc Expiration D (Month/Day/\)		ate of Securit (ear) Underlyin		ng e Security	8. Price of Derivative Security (Instr. 5)	derivate Security Bene Owner Follow Repo	rities ficially ed wing orted	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exerci	isable	Expiration Date	Title	Amount or Number of Shares	(Ins		saction(s) : 4)		
Warrant (right to purchase)	\$0.2	11/25/2019			P		250,000		11/25/	/2019	11/25/2024	Common Stock	250,000	(1)	25	50,000	D	

## **Explanation of Responses:**

- 1. The common stock and warrants were acquired in a public offering, by Onconova Therapeutics, Inc, of units which included one share of common stock and one warrant. The public offering price for each unit was \$0.20.
- $2.\ Includes\ 190$  shares held jointly with Dr. Mehta's spouse.
- 3. Dr. Mehta, as managing member, has voting and dispositive power with regard to the shares held by Mehta Partners, LLC.
- 4. Dr. Mehta, as trustee, has voting and dispositive power with regard to the shares held by Viram Foundation.

/s/ Mark Guerin as attorney-in-11/27/2019 fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.